<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03682146</url>
  </required_header>
  <id_info>
    <org_study_id>LAP-01</org_study_id>
    <nct_id>NCT03682146</nct_id>
  </id_info>
  <brief_title>Laparoscopic and Robot-Assisted Radical Prostatectomy - a Comparative Study</brief_title>
  <acronym>LAP-01</acronym>
  <official_title>A Multicenter Randomized Study to Investigate the Outcomes of Laparoscopic and Robot Radical Prostatectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Leipzig</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Universitätsklinikum Düsseldorf</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Heidelberg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Klinikum Dortmund</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universitätsklinikum Leipzig</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Leipzig</source>
  <brief_summary>
    <textblock>
      Men with localized prostate cancer are analyzed. Purpose: This randomized study compares
      outcomes between robotic-assisted radical prostatectomy and laparoscopic radical
      prostatectomy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In recent years robotic-assisted laparoscopic prostatectomy has assumed significant
      importance in the surgical management of localised prostate cancer. However there is no high
      quality evidence proving the superiority of the robotic approach over conventional
      laparoscopic prostatectomy. The study aims to evaluate functional and oncological outcomes
      between the two approaches. In terms of clinical values, oncologic and continence outcomes,
      erectile function as well as quality of life - patient satisfaction and psychosocial
      orientation will be investigated.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Continence restoration at month 3</measure>
    <time_frame>after 3 months</time_frame>
    <description>Subjective report of urinary continence at month 3; R-LRPE vs. LRPE</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Outcome of continence - Report of continence using the incontinence-specific quality of life outcome questionnaire ICIQ-SF (International Consultation on Incontinence Questionnaire - Short Form)</measure>
    <time_frame>1, 3, 6, 12 months postoperative</time_frame>
    <description>The ICIQ-SF is a subjective measure of severity of urinary loss and quality of life for those with urinary incontinence. The ICIQ is a self-reported survey and screening tool for incontinence. Four main items (of 6 total) ask for rating of symptoms in the past 4 weeks. The sum score of items 3, 4, 5 (items 1 and 2 are demographic) for the actual score is taken. The final item is a self diagnostic item that is unscored. Score is 0 - 21 with a higher score indicating greater severity. Cut-Off Scores: Slight = 1 - 5, Moderate = 6 - 12, Severe = 13 - 18, Very severe = 19 - 21.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Outcome of continence - number of incontinent episodes</measure>
    <time_frame>1, 3, 6, 12 months postoperative</time_frame>
    <description>Report of the number of incontinent episodes [PAD-use/day]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Outcome of erectile function - IIEF-5</measure>
    <time_frame>1, 3, 6, 12 months postoperative</time_frame>
    <description>Erectile function including information by the International Index of Erectile Function [IIEF-5]. The IIEF-5 score is the sum of the ordinal responses to the 5 items. 22-25: No erectile dysfunction, 17-21: Mild erectile dysfunction, 12-16: Mild to moderate erectile dysfunction, 8-11: Moderate erectile dysfunction, 5-7: Severe erectile dysfunction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Outcome of quality of life - EORTC-QLQ-C30 Questionnaire</measure>
    <time_frame>1, 3, 6, 12 months postoperative</time_frame>
    <description>The EORTC quality of life questionnaire (QLQ) is an integrated system for assessing the healthrelated quality of life (QoL) of cancer patients participating in international clinical trials. The EORTC QLQ-C30 Summary Score is calculated from the mean of 13 of the 15 QLQ-C30 scales (the Global Quality of Life scale and the Financial Impact scale are not included). Prior to calculating the mean, the symptom scales need to be reversed to obtain a uniform direction of all scales. The summary score should only be calculated if all of the required 13 scale scores are available (using scale scores based on the completed items, provided that at least 50% of the items in that scale have been.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Outcome of quality of life - EORTC-QLQ-PR25 Questionnaire</measure>
    <time_frame>1, 3, 6, 12 months postoperative</time_frame>
    <description>The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire PR25 contains 25 items and is meant for use among patients with prostate cancer varying in disease stage and treatment modality (i.e. surgery, chemotherapy, radiotherapy, etc.). It includes subscales assessing urinary symptoms (9 items), bowel symptoms (4 items), treatment-related symptoms (6 items), and sexual functioning (6 items). Each subscale ranges from 1 (not at all) to 4 (very much). The QLQ-PR25 should always be complemented by the QLQ-C30.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Outcome of quality of life - HADS-D Questionnaire</measure>
    <time_frame>1, 3, 6, 12 months postoperative</time_frame>
    <description>The Hospital Anxiety and Depression Scale is meant to assess anxiety and depression in patients with physical illness. It contains 14 items with subscales ranging from 1 to 4. If a higher value indicates a better or worse outcome varies with each respective item.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Outcome of quality of life - Patient satisfaction</measure>
    <time_frame>1, 3, 6, 12 months postoperative</time_frame>
    <description>Patient satisfaction is measured on a 5-point scale ranging from highly dissatisfied to highly satisfied. Additionally, patients are asked if they would in hindsight make a decision for or against the surgery and if they would advise a friend to undergo surgery under the same circumstances.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSA value</measure>
    <time_frame>1, 3, 6, 12, 24, 36 months postoperative</time_frame>
    <description>Measurement of prostate-specific antigen.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">782</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>R-LRPE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>robot-assisted laparoscopic prostatectomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LRPE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>conventional radical laparoscopic prostatectomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Prostatectomy</intervention_name>
    <description>Comparison of robot-assisted and conventional laparoscopic radical prostatectomy</description>
    <arm_group_label>LRPE</arm_group_label>
    <arm_group_label>R-LRPE</arm_group_label>
    <other_name>robot-assisted laparoscopic radical prostatectomy</other_name>
    <other_name>conventional laparoscopic radical prostatectomy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Exclusion Criteria:

          -  Strong cognitive disturbance

          -  Patients BMI &gt; 35

          -  Current attendant disease as: cirrhosis of the liver, relapse

          -  TNM-System: T4

          -  Within the last three years: Previous malignant tumor, Neoadjuvant therapy

          -  Patient who are immunosuppressed

          -  Patient has a history of intermitted self-catheterization (one year prior to the start
             of the trial)

          -  Disease of dementia, chronic depression or psychosis

          -  chronic urinary tract infection ( five episodes of antibiotic intakes)

          -  dialysis-dependent patients

          -  absent attendance for memorization and report of disease data in context to the study

          -  If the patient had the following treatments within the last three months: Surgery of
             the Sigmoid colon, hemorrhoidectomy, transurethral needle ablation (TUNA),
             osteosynthesis in pelvic area, salvage prostatectomy
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sigrun Holze, PhD</last_name>
    <email>LAP-01@uniklinik-leipzig.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Klinikum Dortmund</name>
      <address>
        <city>Dortmund</city>
        <zip>44137</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Düsseldorf</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>May 15, 2015</study_first_submitted>
  <study_first_submitted_qc>September 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 24, 2018</study_first_posted>
  <last_update_submitted>September 21, 2018</last_update_submitted>
  <last_update_submitted_qc>September 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Leipzig</investigator_affiliation>
    <investigator_full_name>Dr. Sigrun Holze</investigator_full_name>
    <investigator_title>Clinical Trials Research Coordinator</investigator_title>
  </responsible_party>
  <keyword>DaVinci</keyword>
  <keyword>Robot Assisted</keyword>
  <keyword>Prostatectomy</keyword>
  <keyword>Laparoscopy</keyword>
  <keyword>Continence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

